The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Eli Lilly has had a presence in Kinsale since 1978, a relationship that has seen both places prosper and grow across the ...

Robert F. Kennedy Jr. testified in front of largely combative congresspeople on vaccine policy, his MAHA report and more; the ...

China-based MindRank’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved up to 10.5% weight loss in a ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

Eli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...